Connect with us

Government

Weight-loss drugs are a boon to this surprising company (It’s not who you think)

One company is positioning itself to benefit from surging demand for the weight loss drugs Wegovy, Ozempic, and Mounjaro.

Published

on

Americans' long battle with weight has resulted in an endless stream of weight-loss strategies, including fad diets, that have proven ineffective long term. The result is an increasingly more significant number of people at risk of health complications resulting from obesity, including type 2 diabetes.

Three-quarters of the U.S. population is considered obese or overweight, 37 million have type-2 diabetes, and 96 million Americans have prediabetes.

The cost associated with obesity isn’t just deteriorating health. According to the Centers for Disease Control and Prevention, obesity costs the U.S. healthcare system over $173 billion annually.

Fortunately, emerging weight loss medicines, including Novo Nordisk’s  (NVO) - Get Free Report Wegovy, which is also sold as the diabetes drug Ozempic, are providing a new weapon in the battle against obesity.

These drugs are so effective that there’s been a flurry of interest in them, but it’s not just drugmakers that will benefit from soaring sales. Another company with a long record of helping people manage their weight also stands to profit.

Miami Beach, Florida, Walgreens pharmacy, weight management OTC remedies, Slimfast. (Photo by: Jeffrey Greenberg/UCG/Universal Images Group via Getty Images)

Jeff Greenberg/Getty Images

Obesity faces a new enemy

Doctors evaluate healthy weight using the body mass index (BMI), which measures body fat in adults by dividing weight by height.

Generally, a healthy weight is a BMI between 18.5 and 25. A BMI between 25 to 30 is considered overweight, while a person with a BMI above 30 is considered obese.

Studies have shown that higher BMIs are associated with a higher risk of adverse outcomes, including diabetes and cardiovascular disease.

Related: Viral Weight Loss Drugs Like Ozempic and Wegovy Sell For $10,000. Here's Why.

Excess weight also puts people at greater risk of severe COVID-19 complications.

The relationship between weight and health makes controlling weight important. However, it’s easier said than done for most people because weight programs can be complex or overly restrictive.

As a result, people often experience yo-yo dieting. They lose weight by adhering to diet plans, such as keto or paleo, blood type, or Atkins diets, only to regain weight after stopping.

Since diet programs fall short for many, doctors have relied on other long-term solutions, such as bariatric surgery, for those with health complications. These surgeries, which reshape the digestive system, are effective but costly and potentially risky.

Clearly, there’s a significant need for other weight loss alternatives.

The Food and Drug Administration approved Ozempic to lower blood sugar in type 2 diabetics in 2017, and it approved a higher dose formulation of Ozempic to be sold as Wegovy in 2021.

Eli Lilly’s  (LLY) - Get Free Report Mounjaro has a mechanism of action similar to Ozempic/Wegovy. It’s approved for use in type 2 patients, and a decision on its use to treat obesity is expected later this year.

The rapid adoption of these weight loss drugs is based on compelling efficacy and safety. For example, Wegovy reduced weight by 15% after 68 weeks, with manageable side effects in clinical trials. One in three patients lost over 20% of their weight on the drug in the trial.

Mid-stage trial results released earlier this year showed Mounjaro lowered weight by an average of 26% after 88 weeks.

With results like that, it’s easy to understand why sales of these drugs are surging.

Novo Nordisk reported Wegovy sales of $1.1 billion in the second quarter. Management said demand has been so strong that it is limiting the production of lower doses of the drug that are used when new patients begin treatment to ensure supply for existing patients.

Mounjaro sales were $980 million in the quarter, resulting in total sales of $1.5 billion through the first six months of the year, and that’s without the official FDA stamp of approval for use in obesity.

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images)

UCG/Getty Images

A surprising beneficiary of weight loss drugs emerges

One weight loss pioneer is going all in on the shift towards prescribing weight loss drugs like Wegovy.

Best known for assigning specific foods a certain number of points and recommending members stick to a maximum daily point allowance, Weight Watchers is repositioning itself as a weight loss healthcare provider.

To limit the risk that its core membership business may decline as more people turn to weight loss drugs, the company, which is now called WW International, acquired telehealth provider Sequence earlier this year for $106 million.

The move instantly propels Weight Watchers into the prescriber role, allowing it to counsel and recommend weight loss drugs to patients like a primary care provider.

The decision to embrace weight loss drugs marked a turn for at least one member of WW’s board.

Oprah Winfrey previously characterized weight loss drugs like Wegovy as “an easy way out.” Now, Winfrey says these drugs are an essential tool for weight loss.

It remains to be seen precisely how profitable prescribing weight loss drugs will be for WW, but Wall Street is optimistic.

Analysts expect revenue to increase to $984 million next year from $901 million this year, and earnings will grow to $0.46 per share from a loss of 14 cents per share in 2023.

Winfrey also appears impressed by the company’s prospects. She owns 1.1 million WW International shares, according to SEC filings.

Sign up to find out what stocks we're buying now (Weight Watchers isn't one of them!)

Read More

Continue Reading

Government

Low Iron Levels In Blood Could Trigger Long COVID: Study

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate…

Published

on

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate iron levels in their blood due to a COVID-19 infection could be at greater risk of long COVID.

(Shutterstock)

A new study indicates that problems with iron levels in the bloodstream likely trigger chronic inflammation and other conditions associated with the post-COVID phenomenon. The findings, published on March 1 in Nature Immunology, could offer new ways to treat or prevent the condition.

Long COVID Patients Have Low Iron Levels

Researchers at the University of Cambridge pinpointed low iron as a potential link to long-COVID symptoms thanks to a study they initiated shortly after the start of the pandemic. They recruited people who tested positive for the virus to provide blood samples for analysis over a year, which allowed the researchers to look for post-infection changes in the blood. The researchers looked at 214 samples and found that 45 percent of patients reported symptoms of long COVID that lasted between three and 10 months.

In analyzing the blood samples, the research team noticed that people experiencing long COVID had low iron levels, contributing to anemia and low red blood cell production, just two weeks after they were diagnosed with COVID-19. This was true for patients regardless of age, sex, or the initial severity of their infection.

According to one of the study co-authors, the removal of iron from the bloodstream is a natural process and defense mechanism of the body.

But it can jeopardize a person’s recovery.

When the body has an infection, it responds by removing iron from the bloodstream. This protects us from potentially lethal bacteria that capture the iron in the bloodstream and grow rapidly. It’s an evolutionary response that redistributes iron in the body, and the blood plasma becomes an iron desert,” University of Oxford professor Hal Drakesmith said in a press release. “However, if this goes on for a long time, there is less iron for red blood cells, so oxygen is transported less efficiently affecting metabolism and energy production, and for white blood cells, which need iron to work properly. The protective mechanism ends up becoming a problem.”

The research team believes that consistently low iron levels could explain why individuals with long COVID continue to experience fatigue and difficulty exercising. As such, the researchers suggested iron supplementation to help regulate and prevent the often debilitating symptoms associated with long COVID.

It isn’t necessarily the case that individuals don’t have enough iron in their body, it’s just that it’s trapped in the wrong place,” Aimee Hanson, a postdoctoral researcher at the University of Cambridge who worked on the study, said in the press release. “What we need is a way to remobilize the iron and pull it back into the bloodstream, where it becomes more useful to the red blood cells.”

The research team pointed out that iron supplementation isn’t always straightforward. Achieving the right level of iron varies from person to person. Too much iron can cause stomach issues, ranging from constipation, nausea, and abdominal pain to gastritis and gastric lesions.

1 in 5 Still Affected by Long COVID

COVID-19 has affected nearly 40 percent of Americans, with one in five of those still suffering from symptoms of long COVID, according to the U.S. Centers for Disease Control and Prevention (CDC). Long COVID is marked by health issues that continue at least four weeks after an individual was initially diagnosed with COVID-19. Symptoms can last for days, weeks, months, or years and may include fatigue, cough or chest pain, headache, brain fog, depression or anxiety, digestive issues, and joint or muscle pain.

Tyler Durden Sat, 03/09/2024 - 12:50

Read More

Continue Reading

Government

Walmart joins Costco in sharing key pricing news

The massive retailers have both shared information that some retailers keep very close to the vest.

Published

on

As we head toward a presidential election, the presumed candidates for both parties will look for issues that rally undecided voters. 

The economy will be a key issue, with Democrats pointing to job creation and lowering prices while Republicans will cite the layoffs at Big Tech companies, high housing prices, and of course, sticky inflation.

The covid pandemic created a perfect storm for inflation and higher prices. It became harder to get many items because people getting sick slowed down, or even stopped, production at some factories.

Related: Popular mall retailer shuts down abruptly after bankruptcy filing

It was also a period where demand increased while shipping, trucking and delivery systems were all strained or thrown out of whack. The combination led to product shortages and higher prices.

You might have gone to the grocery store and not been able to buy your favorite paper towel brand or find toilet paper at all. That happened partly because of the supply chain and partly due to increased demand, but at the end of the day, it led to higher prices, which some consumers blamed on President Joe Biden's administration.

Biden, of course, was blamed for the price increases, but as inflation has dropped and grocery prices have fallen, few companies have been up front about it. That's probably not a political choice in most cases. Instead, some companies have chosen to lower prices more slowly than they raised them.

However, two major retailers, Walmart (WMT) and Costco, have been very honest about inflation. Walmart Chief Executive Doug McMillon's most recent comments validate what Biden's administration has been saying about the state of the economy. And they contrast with the economic picture being painted by Republicans who support their presumptive nominee, Donald Trump.

Walmart has seen inflation drop in many key areas.

Image source: Joe Raedle/Getty Images

Walmart sees lower prices

McMillon does not talk about lower prices to make a political statement. He's communicating with customers and potential customers through the analysts who cover the company's quarterly-earnings calls.

During Walmart's fiscal-fourth-quarter-earnings call, McMillon was clear that prices are going down.

"I'm excited about the omnichannel net promoter score trends the team is driving. Across countries, we continue to see a customer that's resilient but looking for value. As always, we're working hard to deliver that for them, including through our rollbacks on food pricing in Walmart U.S. Those were up significantly in Q4 versus last year, following a big increase in Q3," he said.

He was specific about where the chain has seen prices go down.

"Our general merchandise prices are lower than a year ago and even two years ago in some categories, which means our customers are finding value in areas like apparel and hard lines," he said. "In food, prices are lower than a year ago in places like eggs, apples, and deli snacks, but higher in other places like asparagus and blackberries."

McMillon said that in other areas prices were still up but have been falling.

"Dry grocery and consumables categories like paper goods and cleaning supplies are up mid-single digits versus last year and high teens versus two years ago. Private-brand penetration is up in many of the countries where we operate, including the United States," he said.

Costco sees almost no inflation impact

McMillon avoided the word inflation in his comments. Costco  (COST)  Chief Financial Officer Richard Galanti, who steps down on March 15, has been very transparent on the topic.

The CFO commented on inflation during his company's fiscal-first-quarter-earnings call.

"Most recently, in the last fourth-quarter discussion, we had estimated that year-over-year inflation was in the 1% to 2% range. Our estimate for the quarter just ended, that inflation was in the 0% to 1% range," he said.

Galanti made clear that inflation (and even deflation) varied by category.

"A bigger deflation in some big and bulky items like furniture sets due to lower freight costs year over year, as well as on things like domestics, bulky lower-priced items, again, where the freight cost is significant. Some deflationary items were as much as 20% to 30% and, again, mostly freight-related," he added.

Read More

Continue Reading

Government

Walmart has really good news for shoppers (and Joe Biden)

The giant retailer joins Costco in making a statement that has political overtones, even if that’s not the intent.

Published

on

As we head toward a presidential election, the presumed candidates for both parties will look for issues that rally undecided voters. 

The economy will be a key issue, with Democrats pointing to job creation and lowering prices while Republicans will cite the layoffs at Big Tech companies, high housing prices, and of course, sticky inflation.

The covid pandemic created a perfect storm for inflation and higher prices. It became harder to get many items because people getting sick slowed down, or even stopped, production at some factories.

Related: Popular mall retailer shuts down abruptly after bankruptcy filing

It was also a period where demand increased while shipping, trucking and delivery systems were all strained or thrown out of whack. The combination led to product shortages and higher prices.

You might have gone to the grocery store and not been able to buy your favorite paper towel brand or find toilet paper at all. That happened partly because of the supply chain and partly due to increased demand, but at the end of the day, it led to higher prices, which some consumers blamed on President Joe Biden's administration.

Biden, of course, was blamed for the price increases, but as inflation has dropped and grocery prices have fallen, few companies have been up front about it. That's probably not a political choice in most cases. Instead, some companies have chosen to lower prices more slowly than they raised them.

However, two major retailers, Walmart (WMT) and Costco, have been very honest about inflation. Walmart Chief Executive Doug McMillon's most recent comments validate what Biden's administration has been saying about the state of the economy. And they contrast with the economic picture being painted by Republicans who support their presumptive nominee, Donald Trump.

Walmart has seen inflation drop in many key areas.

Image source: Joe Raedle/Getty Images

Walmart sees lower prices

McMillon does not talk about lower prices to make a political statement. He's communicating with customers and potential customers through the analysts who cover the company's quarterly-earnings calls.

During Walmart's fiscal-fourth-quarter-earnings call, McMillon was clear that prices are going down.

"I'm excited about the omnichannel net promoter score trends the team is driving. Across countries, we continue to see a customer that's resilient but looking for value. As always, we're working hard to deliver that for them, including through our rollbacks on food pricing in Walmart U.S. Those were up significantly in Q4 versus last year, following a big increase in Q3," he said.

He was specific about where the chain has seen prices go down.

"Our general merchandise prices are lower than a year ago and even two years ago in some categories, which means our customers are finding value in areas like apparel and hard lines," he said. "In food, prices are lower than a year ago in places like eggs, apples, and deli snacks, but higher in other places like asparagus and blackberries."

McMillon said that in other areas prices were still up but have been falling.

"Dry grocery and consumables categories like paper goods and cleaning supplies are up mid-single digits versus last year and high teens versus two years ago. Private-brand penetration is up in many of the countries where we operate, including the United States," he said.

Costco sees almost no inflation impact

McMillon avoided the word inflation in his comments. Costco  (COST)  Chief Financial Officer Richard Galanti, who steps down on March 15, has been very transparent on the topic.

The CFO commented on inflation during his company's fiscal-first-quarter-earnings call.

"Most recently, in the last fourth-quarter discussion, we had estimated that year-over-year inflation was in the 1% to 2% range. Our estimate for the quarter just ended, that inflation was in the 0% to 1% range," he said.

Galanti made clear that inflation (and even deflation) varied by category.

"A bigger deflation in some big and bulky items like furniture sets due to lower freight costs year over year, as well as on things like domestics, bulky lower-priced items, again, where the freight cost is significant. Some deflationary items were as much as 20% to 30% and, again, mostly freight-related," he added.

Read More

Continue Reading

Trending